BDSX
BDSX clinical trials: BIODESIX INC
Every trial on ClinicalTrials.gov where BIODESIX INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 5
- As lead sponsor
- 5
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
BDSX on the catalyst calendar · BDSX registry changes
- Primary completion Nov 2030Sponsor estimateNo phase registeredNCT07858552Nodify Lung Testing for Pulmonary NodulesBiodesix, Inc. · Indeterminate Pulmonary NoduleNot yet recruitingBDSXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2025Sponsor estimateNo phase registeredNCT04171492Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung NodulesBiodesix, Inc. · Nodule Solitary PulmonaryActive, not recruitingBDSXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2025Sponsor estimateNo phase registeredNCT03289780Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC SubjectsBiodesix, Inc. · Non-Small Cell Lung CancerActive, not recruitingBDSXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2026Sponsor estimateNo phase registeredNCT06728319A Multicenter, Retrospective, Chart Review Study Evaluating the Impact and Utility of the Blood-Based Proteomic Integrated Classifier...Biodesix, Inc. · Lung NodulesActive, not recruitingBDSXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 12, 2022ActualNo phase registeredNCT03766958A Registry to Evaluate the Performance of the BDX-XL2 TestBiodesix, Inc. · Nodule Solitary PulmonaryCompletedBDSXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2015ActualPhase 3NCT01652469Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.ETOP IBCSG Partners Foundation · Carcinoma, Non-Small-Cell LungCompletedBDSXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2023ActualNo phase registeredNCT04676386Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of...Addario Lung Cancer Medical Institute · NSCLC Stage IVTerminatedBDSXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 30, 2022ActualNo phase registeredNCT03951012Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC ImmunotherapyMuhammad Furqan · Non Small Cell Lung CancerTerminatedBDSXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2017ActualPhase 2NCT02318368A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic...AVEO Pharmaceuticals, Inc. · Non-small Cell Lung CancerTerminatedBDSXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 27, 2020ActualPhase 2NCT04100330A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid LeukemiaAVEO Pharmaceuticals, Inc. · Acute Myeloid LeukemiaWithdrawnBDSXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner